XBIO
Xenetic Biosciences, Inc.
Key Financials
Gross Profit
$0
↓ 100.0%
Revenue
$3.0M
↑ 19.0%
Operating Income
$-2834582
↑ 32.6%
Total Liabilities
$968025.00
↑ 8.2%
Total Assets
$8.4M
↑ 21.2%
EPS (Diluted)
$-1.58
↑ 38.5%
Net Income
$-2680860
↑ 32.3%
Shareholders' Equity
$7.4M
↑ 23.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 5/29/2026 | View on SEC |
| SCHEDULE 13G/A | 5/14/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| 10-K/A | 4/24/2026 | View on SEC |
| 8-K | 4/24/2026 | View on SEC |
| 4 | 4/23/2026 | View on SEC |
| 8-K | 3/13/2026 | View on SEC |
| 10-K | 3/12/2026 | View on SEC |
| SCHEDULE 13G | 2/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | XBIO |
| Company Name | Xenetic Biosciences, Inc. |
| CIK | 1534525 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 781-778-7720 |